{
  "company": "CIPLA",
  "report_date": "August 07, 2019",
  "filename": "CIPLA_transcript_Aug_2019.pdf",
  "quarter": "Q1",
  "fiscal_year": "2020",
  "management_team": [
    "MR. UMANG VOHRA - MANAGING DIRECTOR AND",
    "MR. KEDAR UPADHYE - GLOBAL CHIEF FINANCIAL",
    "MR. NAVEEN BANSAL - INVESTOR RELATIONS TEAM -",
    "UMANG VOHRA - MANAGING DIRECTOR AND",
    "EXECUTIVE OFFICER - CIPLA LIMITED",
    "KEDAR UPADHYE - GLOBAL CHIEF FINANCIAL",
    "OPERATING OFFICER - CIPLA LIMITED",
    "NAVEEN BANSAL - INVESTOR RELATIONS TEAM -"
  ],
  "moderator": "Ladies and gentlemen good day and welcome to Cipla Q1 FY2020 Earnings Conference \nCall hosted by Kotak Securities Limited",
  "analysts": [
    {
      "name": "Prakash Agarwal",
      "firm": "Axis Capital"
    },
    {
      "name": "Anubhav Agarwal",
      "firm": "Credit \nSuisse"
    },
    {
      "name": "Neha Manpuria",
      "firm": "JP Morgan"
    },
    {
      "name": "Nimish Mehta",
      "firm": "Research Delta \nAdvisors"
    },
    {
      "name": "Kunal Dhamesha",
      "firm": "SBI Capital"
    },
    {
      "name": "Abhishek Sharma",
      "firm": "IIFL"
    },
    {
      "name": "Surya Patra",
      "firm": "PhillipCapital"
    },
    {
      "name": "Ujwal Shah",
      "firm": "Quest Investment \nAdvisors"
    },
    {
      "name": "Nitin Agarwal",
      "firm": "IDFC \nSecurities"
    },
    {
      "name": "Krishnendu Shah",
      "firm": "Quantum \nMutual Fund"
    },
    {
      "name": "Shyam Srinivasan",
      "firm": "Goldman \nSachs"
    },
    {
      "name": "Vishal Sharma",
      "firm": "Nirmal Bang"
    },
    {
      "name": "Ritika Agarwal",
      "firm": "Quest \nInvestments"
    },
    {
      "name": "Charulata Gaidhani",
      "firm": "Dalal & \nBroacha"
    }
  ],
  "qa_segments": [],
  "key_financial_metrics": {
    "sales_inr_crores": "1132",
    "growth_percentage": "1.3"
  },
  "business_highlights": [
    "partnership with \nAlvotech on Adalimumab for select emerging markets.",
    "acquired the \nrights to Zemdri which is IV form of Plazomicin from Achaogen in a Chapter 11, U.",
    "acquired \nportfolio of Mirren in the OTC space delivered over 10% growth.",
    "acquired by different distributors at different prices, \nthere was a little bit of instability, a fair amount of instability in the trade channel on \naccount of this.",
    "acquired from \nAchaogen."
  ],
  "extraction_metadata": {
    "extraction_date": "2025-08-03T01:08:50.352136",
    "source_file": "data\\cipla\\CIPLA_transcript_Aug_2019.pdf",
    "text_length": 63566,
    "extraction_method": "PyMuPDF + Regex parsing + Filename analysis"
  }
}